ArticleFrontiers in pharmacology2022
Tongxinluo May Alleviate Inflammation and Improve the Stability of Atherosclerotic Plaques by Changing the Intestinal Flora.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 6 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Tongxinluo for the Secondary Prevention of Atherosclerotic Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Brain and behavior · 2026Pooled it
- Pooled it
- The NLRP3 inflammasome: a therapeutic target of phytochemicals in treating atherosclerosis (a systematic review).Frontiers in immunology · 2025Pooled it
- Gut microbiota regulate atherosclerosis via the gut-vascular axis: a scoping review of mechanisms and therapeutic interventions.Frontiers in microbiology · 2025Pooled it
- Tongxinluo capsule for acute myocardial infarction: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2024Pooled it
- Coronary atherosclerotic plaque intervention with Tongxinluo capsule (TXL-CAP): a multicenter, randomized, double-blind and placebo-controlled study.Signal transduction and targeted therapy · 2026Trial
- Comparative efficacy and safety of oral Chinese patent medicines combined with conventional therapy for coronary heart disease complicated by diabetes: a systematic review and network meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- An Up-to-Date Review of Traditional Chinese Medicine in the Treatment of Atherosclerosis: Components, Mechanisms, and Therapeutic Potentials.Phytotherapy research : PTR · 2025Review
- Study design and rationale of the TXL-CAP trial: a randomized, double-blind, placebo-controlled, multicenter clinical trial assessing the effect of Tongxinluo capsules on the stability of coronary atherosclerotic plaques.Journal of geriatric cardiology : JGC · 2025Article
- Research progress of regulating intestinal flora by traditional Chinese medicine in treating coronary heart disease.Chinese herbal medicines · 2025Review
- Dietary supplementation with milk-derivediMetaOmics · 2025Article
- The oral-gut microbiota axis: a link in cardiometabolic diseases.NPJ biofilms and microbiomes · 2025Review
- Expert Consensus on the Diagnosis and Management of Carotid Atherosclerotic Plaque: Pathophysiology, Clinical Management, and Preventive Approaches.International journal of medical sciences · 2025Review
- Translational Research and Clinical Application of Traditional Chinese Medicine in Cardiovascular Diseases.JACC. Asia · 2024Review
- Review
- Review
- Efficacy and safety of tongxinluo capsule for angina pectoris of coronary heart disease: an overview of systematic reviews and meta-analysis.Frontiers in cardiovascular medicine · 2024Review
- Intestinal mucosal barrier: a potential target for traditional Chinese medicine in the treatment of cardiovascular diseases.Frontiers in pharmacology · 2024Review
- Comparative efficacy of Chinese patent medicines in patients with carotid atherosclerotic plaque: a Bayesian network meta- analysis.Chinese medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal flora plays an important role in atherosclerosis. Tongxinluo, as a multi-target Chinese medicine to improve atherosclerosis, whether it can improve atherosclerosis by affecting the intestinal flora is worth exploring. We established a vulnerable plaque model of atherosclerosis in New Zealand white rabbits by high cholesterol diet and balloon injury (HCB), and performed Tongxinluo intervention. We detected the level of inflammation by immunohistochemistry, Western Blot, and ELISA, analyzed plaque characteristics by calculating the vulnerability index, and analyzed the changes of gut microbiota and metabolites by 16S rRNA gene sequencing and untargeted metabolomic sequencing. The results showed that Tongxinluo intervention improved plaque stability, reduced inflammatory response, inhibited NLRP3 inflammatory pathway, increased the relative abundance of beneficial bacteria such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.